Policy Blog

This week, Congress is out but everyone else seems to be in!

The payment rules are here!

This week: It’s HOT! That is all!

This week features zombie cicadas, drug shortages, and some surprising placeholders being set by members of Congress who don’t plan to be around next year.

DC-types thinking big thoughts on healthcare just in time for the Trump hush money verdict. Cue the clowns!

This week, the Wall St. Journal predicts the end of the gravy train for MA plans, while Congress (and FDA finally) turn their attention to clinical trials, among other health priorities.

We see our first glimpse of guidance implementing the second round of drug price negotiations as the Administration seeks to shore up its healthcare legacy ahead of election deadlines.

This week, legislators have been preoccupied with appropriations deadlines while the FDA plans to hold a meeting about whether or not they have too many meetings.

This week site neutral payment policy wins some important allies while others look to keep health care quality, PBM reform, MA marketing rules, and data sharing concerns relevant.